Clinical Trial Update: Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating peretinoin for suppressing recurrence of hepatitis C virus–positive hepatocellular carcinoma has completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Neoplasm
• Hepatocellular Carcinoma

Drugs mentioned

• Peretinoin (peretinoin)

Snippet

Sponsor: Kowa Company, Ltd. | Conditions: Hepatic Neoplasm Malignant Recurrent | Phase 3 | Status: COMPLETED | Results posted: 2020-12-02